Abundant scientific evidence suggests that many age-related conditions result from pathological interactions between selected metals and target proteins. The company has developed a proprietary library of chemical compounds that target these interactions, preventing protein aggregation and corruption.

The mission of the company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration.